Lake Street Capital Boosts Envoy Medical (NASDAQ:COCH) Price Target to $6.00

Envoy Medical (NASDAQ:COCHFree Report) had its target price upped by Lake Street Capital from $3.00 to $6.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, Northland Securities began coverage on shares of Envoy Medical in a report on Thursday, December 21st. They set an outperform rating on the stock.

Check Out Our Latest Stock Report on Envoy Medical

Envoy Medical Stock Up 22.3 %

Envoy Medical stock opened at $5.48 on Wednesday. The company’s 50 day moving average is $3.48. Envoy Medical has a fifty-two week low of $0.75 and a fifty-two week high of $11.72.

Hedge Funds Weigh In On Envoy Medical

An institutional investor recently bought a new position in Envoy Medical stock. Weiss Asset Management LP acquired a new stake in shares of Envoy Medical, Inc. (NASDAQ:COCHFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $37,000. Weiss Asset Management LP owned 0.10% of Envoy Medical as of its most recent SEC filing. Institutional investors and hedge funds own 8.59% of the company’s stock.

Envoy Medical Company Profile

(Get Free Report)

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.

Further Reading

Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.